Ulcerative colitis (UC) can lead to progressive intestinal damage and massive restrictions in the daily lives of those affected [2]. With the approval of SKYRIZI® (risankizumab), a new first-line therapy is now available to UC patients [1]. Data from pivotal phase 3 clinical trials show rapid and sustained efficacy and make long-term goals such as mucosal healing achievable in up to 76% of patients without prior biologic failure$ possible [3, 4].
You May Also Like
- DOAK optimization, ABC pathway and lessons learned from the FXI/XIa pipeline
Stroke prevention for atrial fibrillation 2025
- From symptom to diagnosis
Abdominal pain – Hernias
- "Survey of Health, Ageing and Retirement in Europe" (SHARE)
Analysis of polypharmacy in ≥65-year-olds
- New perspectives for clinics and research
Ageing, cellular senescence and Parkinson’s disease
- From early intervention to individualization
The new guidelines at a glance
- Artificial intelligence
Dr. ChatGPT: Large language models in everyday clinical practice
- Focus on prevention
Colorectal cancer screening – an update
- COPD therapy